Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

BACKGROUND: This study investigated the cardiovascular (CV) safety profile of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin versus comparator treatments. METHODS: This was a pre-specified meta-analysis of CV events in linagliptin or comparator-treated patients with type 2 diabetes mellitus...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansen, Odd Erik, Neubacher, Dietmar, von Eynatten, Maximilian, Patel, Sanjay, Woerle, Hans-Juergen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286367/
https://www.ncbi.nlm.nih.gov/pubmed/22234149
http://dx.doi.org/10.1186/1475-2840-11-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286367/
https://www.ncbi.nlm.nih.gov/pubmed/22234149
http://dx.doi.org/10.1186/1475-2840-11-3

Ejemplares similares